Skip to content
A1962Assembly2023-2024 SessionSame asS2393

Give Drug Rebates to Patients

Official title

“Relates to requiring certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale”

Sponsor Latrice WalkerAD-55+17 co-sponsorsAffects Finance
Status
In Assembly Committee
Insurance
Impact
8/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

This bill requires health insurers to pass at least 85% of prescription drug rebates directly to patients at the point of sale.

Why it matters

  1. Shifts drug rebate savings directly to patients. By mandating that at least 85% of all prescription drug rebates go to patients at the point of sale, the bill aims to lower out-of-pocket costs for those with high drug expenses, rather than letting insurers retain most of the savings.

  2. Broad applicability across state-regulated plans. The requirements apply to nearly all state-regulated health insurers, including employer plans for state and local workers, ensuring widespread impact across New Yorkers with commercial insurance coverage.

  3. Increased transparency and oversight, but with confidentiality. Insurers must annually certify compliance to the state, creating a new layer of oversight, yet the law keeps the actual rebate amounts confidential to protect proprietary and competitive information.

  4. Potential impact on insurance premiums and market dynamics. While patients may pay less at the pharmacy counter, insurers losing a portion of rebate revenue could adjust premiums or plan designs elsewhere, possibly affecting overall insurance costs or coverage options.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Patients with prescription drug deductibles or coinsurance

    The bill would base their point-of-sale cost sharing on a drug price reduced by at least 85% of rebates received or expected for that drug.

  • Health insurers and state or local governmental employer plans

    They would have to apply the rebate-based calculation and certify compliance for the prior calendar year to the superintendent by January 1 each year.

  • Insurance regulators

    The superintendent would establish the certification form and receive annual compliance certifications.

  • Insurers’ vendors and downstream service providers

    Those with access to rebate information would be subject to confidentiality protections imposed by insurers, including restrictions on public disclosure of detailed rebate amounts.

Headline styles

Give Drug Rebates to Patients

Plain English, a few words. Used as the page title.

Sponsors

History

  1. Print number 1962a
  2. Amend (t) and recommit to insurance
  3. Referred to insurance
  4. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S2393Senate

Drug Rebates Go To Patients

In Senate Committee · Finance · Sponsor Robert Jackson

Impact 8 · Significant0% to pass

Full text

4 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

1962--A

2023-2024 Regular Sessions

IN ASSEMBLY

January 23, 2023

Introduced by M. of A. WALKER, DILAN, TAPIA, ALVAREZ, REYES, HYNDMAN, SEPTIMO, DE LOS SANTOS, ZACCARO -- read once and referred to the Committee on Insurance -- recommitted to the Committee on Insurance in accordance with Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the insurance law and the public health law, in relation to requiring certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. The insurance law is amended by adding a new section 3246 to read as follows:

§ 3246. Ensuring fairness in certain cost sharing. (a) As used in this section, the following terms shall have the following meanings:

(1) "Defined cost sharing" means a deductible payment or coinsurance amount imposed on an enrollee for a covered prescription drug under the enrollee's health plan.

(2) "Insurer" means any health insurance issuer that is subject to state law regulating insurance and offers health insurance coverage, as defined in 42 U.S.C. § 300gg-91, or any state or local governmental employer plan.

(3) "Price protection rebate" means a negotiated price concession that accrues directly or indirectly to the insurer, or other party on behalf of the insurer, in the event of an increase in the wholesale acquisition cost of a drug above a specified threshold.

(4) "Rebate" means:

(A) Negotiated price concessions including but not limited to base price concessions, whether described as a rebate or otherwise, and reasonable estimates of any price protection rebates and performance-

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD05427-05-3

based price concessions that may accrue directly or indirectly to the insurer during the coverage year from a manufacturer, dispensing pharmacy, or other party in connection with the dispensing or administration of a prescription drug, and

(B) Reasonable estimates of any negotiated price concessions, fees and other administrative costs that are passed through, or are reasonably anticipated to be passed through, to the insurer and serve to reduce the insurer's liabilities for a prescription drug.

(b) An enrollee's defined cost sharing for each prescription drug shall be calculated at the point of sale based on a price that is reduced by an amount equal to at least eighty-five percent of all rebates received, or to be received, in connection with the dispensing or administration of the prescription drug. Nothing shall preclude an insurer from decreasing an enrollee's defined cost sharing by an amount greater than that required under this subsection.

(c) An insurer shall submit to the superintendent by the first of January of each year a certification in a form to be established by the superintendent attesting that it has complied with the requirements of subsection (b) of this section for the prior calendar year.

(d) In complying with the provisions of this section, an insurer or its agents shall not publish or otherwise publicly reveal information regarding the actual amount of rebates an insurer receives on a product or therapeutic class of products, manufacturer, or pharmacy-specific basis. Such information shall be exempt from disclosure under section eighty-seven of the public officers law and shall not be disclosed directly or indirectly, or in a manner that would allow for the identification of an individual product, therapeutic class of products, or manufacturer, or in a manner that would have the potential to compromise the financial, competitive, or proprietary nature of such information. An insurer shall impose the confidentiality protections of this subdivision on any vendor or downstream third-party that performs health care or administrative services on behalf of the insurer that may receive or have access to rebate information.

§ 2. The insurance law is amended by adding a new section 4331 to read as follows:

§ 4331. Ensuring fairness in certain cost sharing. (a) As used in this section, the following terms shall have the following meanings:

(1) "Defined cost sharing" means a deductible payment or coinsurance amount imposed on an enrollee for a covered prescription drug under the enrollee's health plan.

(2) "Corporation" means any health insurance issuer that is subject to state law regulating insurance and offers health insurance coverage, as defined in 42 U.S.C. § 300gg-91, or any state or local governmental employer plan.

(3) "Price protection rebate" means a negotiated price concession that accrues directly or indirectly to the corporation, or other party on behalf of the corporation, in the event of an increase in the wholesale acquisition cost of a drug above a specified threshold.

(4) "Rebate" means:

(A) Negotiated price concessions including but not limited to base price concessions, whether described as a rebate or otherwise, and reasonable estimates of any price protection rebates and performancebased price concessions that may accrue directly or indirectly to the corporation during the coverage year from a manufacturer, dispensing pharmacy, or other party in connection with the dispensing or administration of a prescription drug, and

(B) Reasonable estimates of any negotiated price concessions, fees and other administrative costs that are passed through, or are reasonably anticipated to be passed through, to the corporation and serve to reduce the corporation's liabilities for a prescription drug.

(b) An enrollee's defined cost sharing for each prescription drug shall be calculated at the point of sale based on a price that is reduced by an amount equal to at least eighty-five percent of all rebates received, or to be received, in connection with the dispensing or administration of the prescription drug. Nothing shall preclude a corporation from decreasing an enrollee's defined cost sharing by an amount greater than that required under this subsection.

(c) A corporation shall submit to the superintendent by the first of January of each year a certification in a form to be established by the superintendent attesting that it has complied with the requirements of subsection (b) of this section for the prior calendar year.

(d) In complying with the provisions of this section, a corporation or its agents shall not publish or otherwise publicly reveal information regarding the actual amount of rebates a corporation receives on a product or therapeutic class of products, manufacturer, or pharmacy-specific basis. Such information shall be exempt from disclosure under section eighty-seven of the public officers law and shall not be disclosed directly or indirectly, or in a manner that would allow for the identification of an individual product, therapeutic class of products, or manufacturer, or in a manner that would have the potential to compromise the financial, competitive, or proprietary nature of such information. A corporation shall impose the confidentiality protections of this subdivision on any vendor or downstream third-party that performs health care or administrative services on behalf of the corporation that may receive or have access to rebate information.

§ 3. The public health law is amended by adding a new section 4417 to read as follows:

§ 4417. Ensuring fairness in certain cost sharing. 1. As used in this section, the following terms shall have the following meanings:

(a) "Defined cost sharing" means a deductible payment or coinsurance amount imposed on an enrollee for a covered prescription drug under the enrollee's health plan.

(b) "Organization" means any health insurance issuer that is subject to state law regulating insurance and offers health insurance coverage, as defined in 42 U.S.C. § 300gg-91, or any state or local governmental employer plan.

(c) "Price protection rebate" means a negotiated price concession that accrues directly or indirectly to the organization, or other party on behalf of the organization, in the event of an increase in the wholesale acquisition cost of a drug above a specified threshold.

(d) "Rebate" means:

(i) Negotiated price concessions including but not limited to base price concessions, whether described as a rebate or otherwise, and reasonable estimates of any price protection rebates and performancebased price concessions that may accrue directly or indirectly to the organization during the coverage year from a manufacturer, dispensing pharmacy, or other party in connection with the dispensing or administration of a prescription drug, and

(ii) Reasonable estimates of any negotiated price concessions, fees and other administrative costs that are passed through, or are reasonably anticipated to be passed through, to the organization and serve to reduce the organization's liabilities for a prescription drug.

2. An enrollee's defined cost sharing for each prescription drug shall be calculated at the point of sale based on a price that is reduced by an amount equal to at least eighty-five percent of all rebates received, or to be received, in connection with the dispensing or administration of the prescription drug. Nothing shall preclude an organization from decreasing an enrollee's defined cost sharing by an amount greater than that required under this subdivision.

3. An organization shall submit to the superintendent by the first of January of each year a certification in a form to be established by the superintendent attesting that it has complied with the requirements of subdivision two of this section for the prior calendar year.

4. In complying with the provisions of this section, an organization or its agents shall not publish or otherwise publicly reveal information regarding the actual amount of rebates an organization receives on a product or therapeutic class of products, manufacturer, or pharmacy-specific basis. Such information shall be exempt from disclosure under section eighty-seven of the public officers law and shall not be disclosed directly or indirectly, or in a manner that would allow for the identification of an individual product, therapeutic class of products, or manufacturer, or in a manner that would have the potential to compromise the financial, competitive, or proprietary nature of such information. An organization shall impose the confidentiality protections of this subdivision on any vendor or downstream third-party that performs health care or administrative services on behalf of the organization that may receive or have access to rebate information.

§ 4. This act shall take effect immediately and apply to contracts issued, renewed or amended on or after January 1, 2023.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.